Pt | Age | Cancer | Stage on enrollment | # of cycles | Off-study reason | PFS#(ms) | OS* (ms) | Immune response | |||
---|---|---|---|---|---|---|---|---|---|---|---|
Proliferative assay | Elispot | ||||||||||
 |  |  |  |  |  |  |  | Pre-vaccine | Post-vaccine | Pre-vaccine | Post-vaccine |
1A | 56 | Colon | IV | 2 | PD | 0.5 | 5.5 | ND | |||
2A | 57 | Colon | IV | 3 | PD | 3.9 | 16.8 | NA | - | - | |
3A | 62 | Colon | IV | 3 | PD | 5.8 | 21.5 | - | - | - | - |
4A | 50 | Pancreatic | IV | 3 | PD | 3.6 | 6.2 | - | - | - | - |
5A | 60 | Lung | IV | 1 | PD | 1 | 2.8 | ND | |||
6A | 59 | Colon | IV | 3 | PD | 3.5 | 8.9 | NA | |||
7A | 52 | Colon | NED | 11 | Completed | 129+ | 129+ | - | + | - | + |
8A | 68 | Lung | IV | 3 | PD | 3.6 | 13.1 | - | - | - | - |
9A | 56 | Colon | NED | 10 | PPS | 18.8 | 37.2 | - | + | - | + |
10A | 63 | Colon | IV | 3 | PD | 3.3 | 19.9 | - | - | - | - |
11A | 42 | Pancreatic | NED | 6 | PD | 7.5 | 24.1 | - | - | - | - |
12A | 39 | Colon | NED | 3 | PD | 6.2 | 23 | - | - | - | - |
13A | 67 | Colon | IV | 3 | PD | 3.5 | 4.8 | - | + | + | + |
14A | 51 | Colon | NED | 3 | PD | 7.1 | 41.3 | - | - | - | - |
15A | 60 | Pancreatic | IV | 3 | PPS/Lost to follow-up | 2.7+ | 5.3 | NA | - | - | |
16A | 61 | Colon | IV | 3 | PD | 3.6 | 17.3 | - | + | - | - |